November 29, 2012: Recently the journal Neurology, published four case reports describing different unusual and serious adverse events in patients taking the oral MS drug, fingolimod (Gilenya). Case reports are descriptions of an individual patient, designed to raise awareness in the community of physicians to be on the lookout for very rare occurrences and report them. No conclusion can or should be made from an individual case report, however, the cluster of increasing and unusual complications is troubling. The IMSMP physicians are increasingly concerned regarding the safety of Gilenya in the short and long term. Please contact your IMSMP physician for further information on this matter.
